5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide has been researched along with phenytoin in 7 studies
*Phenytoin: An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [MeSH]
*Phenytoin: An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [MeSH]
| Studies (5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide) | Trials (5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide) | Recent Studies (post-2010) (5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide) | Studies (phenytoin) | Trials (phenytoin) | Recent Studies (post-2010) (phenytoin) |
|---|---|---|---|---|---|
| 8 | 0 | 1 | 14,105 | 758 | 1,497 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dickinson, RG; Fowler, DW; Kluck, RM | 1 |
| Chan, KM; Ladenson, JH; Lichti, DA; McClellan, AC; Meltzer, VN | 1 |
| Montgomery, C; Vore, M | 1 |
| Rainey, PM; Roberts, WL; Rogers, KE | 1 |
| Rainey, PM; Roberts, WL | 1 |
| Hara, Y; Katoh, M; Nakajima, M; Tachibana, O; Yamanaka, H; Yamashita, J; Yokoi, T | 1 |
| Aliwarga, T; Brundage, RC; Cloyd, JC; Goel, V; Leppik, IE; Marino, SE; Remmel, RP | 1 |
7 other study(ies) available for 5-phenyl-5-(4-hydroxyphenyl)hydantoin glucuronide and phenytoin
| Article | Year |
|---|---|
Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta.
Topics: Animals; Antipyrine; Female; Humans; In Vitro Techniques; Male; Maternal-Fetal Exchange; Metabolic Clearance Rate; Perfusion; Phenytoin; Placenta; Pregnancy; Rats; Rats, Inbred Strains; Solubility | 1989 |
Comparison of the EMIT phenytoin procedure with old and new antibodies.
Topics: Antibodies; Creatinine; Cross Reactions; False Positive Reactions; Humans; Immunoenzyme Techniques; Phenytoin | 1984 |
The effect of diethylstilbestrol treatment on the metabolism and biliary excretion of [14C]phenytoin in the isolated perfused rat liver.
Topics: Animals; Bile; Diethylstilbestrol; Female; In Vitro Techniques; Liver; Perfusion; Phenytoin; Rats | 1981 |
Metabolite and matrix interference in phenytoin immunoassays.
Topics: Calibration; Enzyme Multiplied Immunoassay Technique; Fluorescence Polarization; Humans; Immunoassay; Phenytoin; Regression Analysis; Sensitivity and Specificity; Uremia | 1996 |
Phenytoin overview--metabolite interference in some immunoassays could be clinically important.
Topics: Cross Reactions; Humans; Immunoassay; Kidney Failure, Chronic; Phenytoin | 2004 |
Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases.
Topics: Adolescent; Adult; Anticonvulsants; Female; Glucuronosyltransferase; Humans; Male; Middle Aged; Phenytoin; Polymorphism, Genetic | 2005 |
Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Biological Availability; Chromatography, High Pressure Liquid; Drug Monitoring; Epilepsy; Female; Humans; Isotope Labeling; Male; Middle Aged; Phenytoin; Young Adult | 2011 |